New target therapies for brain metastases from breast cancer

Current Cancer Drug Targets

Volumn 12, Issue 3, 2012, Pages 210-217

  Metro, G ^a   Fabi, A ^b  

^a Azienda Ospedaliera Santa Maria della Misericordia   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Blood brain barrier; Brain metastases; Breast cancer; Central nervous system; HER2; Lapatinib; Trastuzumab; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; INIPARIB; IRINOTECAN; JNJ 28871063; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VELIPARIB;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GENE EXPRESSION; GLIOBLASTOMA; HERPES SIMPLEX; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; LIVER CELL CARCINOMA; LUNG EMBOLISM; NEUROSURGEON; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; TUMOR XENOGRAFT; WHOLE BODY RADIATION;

EID: 84857127375     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799277548     Document Type: Article

References (65)

1. Lin, N.U.; Bellon, J. R.; Winer, E.P. CNS metastases in breast cancer. J. Clin. Oncol. 2004, 22, 3608-3617.
2. Sperduto, P. W.; Kased, N.; Roberge, D. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2011. DOI: 10.1016/ijrobp.2011.02.027
3. Piehkowski, T.; Zielinski, C. C. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann. Oncol. 2010, 21, 917-924.
4. Niwihska, A.; Murawska, M.; Pogoda, K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 2010,116, 4238-4247.
5. Eichler, A. F.; Kuter, I.; Ryan, P.; Schapira, L.; Younger, J.; Henson, J. W. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008, 112, 2359-2367.
6. Lin, N. U.; Claus, E.; Sohl, J.; Razzak, A. R.; Arnaout, A.; Winer, E. P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008,113, 2638-2645.
7. Nam, B. H.; Kim, S. Y.; Han, H. S.; Kwon, Y.; Lee, K. S.; Kim, T. H; Ro, J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008,10, R20.
8. Hines, S. L.; Vallow, L. A.; Tan, W. W.; McNeil, R. B.; Perez, E. A.; Jain, A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann. Oncol. 2008,19, 1561-1565.
9. Niwihska, A.; Murawska, M.; Pogoda, K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann. Oncol. 2010, 21, 942-948.
10. Anders, C. K; Deal, A. M.; Miller, C. R.; Khorram, C; Meng, H.; Burrows, E.; Livasy, C; Fritchie, K; Ewend, M. G.; Perou, C. M.; Carey, L. A. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011, 117, 1602-1611.
11. Metro G.; Mottolese, M.; Fabi, A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert. Opin. Pharmacother. 2008, 9, 2583-2601.
12. Palmieri, D.; Bronder, J. L.; Herring, J. M.; Yoneda, T.; Weil, R. J.; Stark, A. M.; Kurek, R.; Vega-Valle, E.; Feigenbaum, L.; Halverson, D.; Vortmeyer, A. O.; Steinberg, S. M.; Aldape, K.; Steeg, P. S. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67, 4190-4198.
13. Pestalozzi, B. C; Zahrieh, D.; Price, K. N.; Holmberg, S. B.; Lindtner, J.; Collins, J.; Crivellari, D.; Fey, M. F.; Murray, E.; Pagani, O.; Simoncini, E.; Castiglione-Gertsch, M.; Gelber, R. D.; Coates, A. S.; Goldhirsch, A.; International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 2006.17, 935-944.
14. Gabos, Z.; Sinha, R.; Hanson, J.; Chauhan, N.; Hugh, J.; Mackey, J. R. Abdulkarim, B. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J. Clin. Oncol. 2006, 24, 5658-5663.
15. Pestalozzi, B. C; Brignoli, S. Trastuzumab in CSF. J. Clin. Oncol. 2000.18, 2349-2351.
16. Stemmler, H. J.; Schmitt, M.; Willems, A.; Bernhard, H.; Harbeck, N.; Heinemann, V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007,18, 23-28.
17. Yonemori, K; Tsuta, K; Ono, M.; Shimizu, C; Hirakawa, A.; Hasegawa, T.; Hatanaka, Y.; Narita, Y.; Shibui, S.; Fujiwara, Y. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010,116, 302-308.
18. Lin, N. U.; Winer, E. P. Brain metastases: the HER2 paradigm. Clin. Cancer Res. 2007,13, 1648-1655.
19. Dijkers, E. C; Oude Munnink, T. H.; Kosterink, J. G.; Brouwers, A. H.; Jager, P. L.; de Jong, J. R.; van Dongen, G. A.; Schröder, C. P.; Lub-de Hooge, M. N.; de Vries, E. G. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87, 586-592.
20. Motl, S.; Zhuang, Y.; Waters, C. M.; Stewart, C. F. Pharmacokinetic considerations in the treatment of CNS tumours. Clin. Pharmacokinet. 2006, 45, 871-903.
21. Laufman, L. R.; Forsthoefel, K. F. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin. Breast Cancer 2001, 2, 235.
22. Stemmler, H. J.; Schmitt, M.; Harbeck, N.; Willems, A.; Bernhard, H; Lässig, D.; Schoenberg, S.; Heinemann, V. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol. Rep. 2006,15, 1373-1377.
23. Platini, C; Long, J.; Walter, S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol. 2006, 7, 778-780.
24. Mir, O.; Ropert, S.; Alexandre, J.; Lemare, F.; Goldwasser, F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann. Oncol. 2008.19, 1978-1980.
25. Colozza, M.; Minenza, E.; Gori, S.; Fenocchio, D.; Paolucci, C.; Aristei, C.; Floridi, P. Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother. Pharmacol. 2009, 63, 1157-1159.
26. Liang, K.; Lu, Y.; Jin, W.; Ang, K. K.; Milas, L.; Fan, Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol. Cancer Ther. 2003, 2, 1113-1120.
27. Chargari, C.; Idrissi, H. R.; Pierga, J. Y.; Bollet, M. A.; Diéras, V.; Campana, F.; Cottu, P.; Fourquet, A.; Kirova, Y. M. preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2010, 81, 631-636.
28. Hu, J.; Ljubimova, J. Y.; Inoue, S.; Konda, B.; Patil, R.; Ding, H.; Espinoza, A.; Wawrowsky, K. A.; Patil, C.; Ljubimov, A. V.; Black, K. L. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 2010, 5, e10108.
29. Kinoshita, M.; McDannold, N.; Jolesz, F. A.; Hynynen, K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 11719-11723.
30. Joo, K. M.; Park, I. H.; Shin, J. Y.; Jin, J.; Kang, B. G.; Kim, M. H.; Lee, S. J.; Jo, M. Y.; Kim, S. U.; Nam, D. H. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol. Ther. 2009, 17, 570-575.
31. Frank, R. T.; Edmiston, M.; Kendall, S. E.; Najbauer, J.; Cheung, C. W.; Kassa, T.; Metz, M. Z.; Kim, S. U.; Glackin, C. A.; Wu, A. M.; Yazaki, P. J.; Aboody, K. S. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One 2009, 4, e8314.
32. Ryan, Q.; Ibrahim, A.; Cohen, M. H.; Johnson, J.; Ko, C. W.; Sridhara, R.; Justice, R.; Pazdur, R. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008, 13, 1114-1119.
33. Gril, B.; Palmieri, D.; Bronder, J.L.; Herring, J. M.; Vega-Valle, E.; Feigenbaum, L.; Liewehr, D. J.; Steinberg, S. M.; Merino, M. J.; Rubin, S. D.; Steeg, P. S. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl. Cancer Inst. 2008, 100, 1092-1103.
34. Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C. G.; Chan, S.; Jagiello-Gruszfeld, A.; Kaufman, B.; Crown, J.; Chan, A.; Campone, M.; Viens, P.; Davidson, N.; Gorbounova, V.; Raats, J. I.; Skarlos, D.; Newstat, B.; Roychowdhury, D.; Paoletti, P.; Oliva, C.; Rubin, S.; Stein, S.; Geyer, C. E. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008, 112, 533-543.
35. Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00820222 [Last accessed 1 March 2011].
36. Costa, S. D.; Jackisch, C.; Thomssen, C. Future roles of lapatinib in erbb2-positive breast cancer: adjuvant and neoadjuvant trials. Breast Care (Basel). 2010, 5(s1), 22-24.
37. Lin, N. U.; Carey, L. A.; Liu, M. C.; Younger, J.; Come, S. E.; Ewend, M.; Harris, G. J.; Bullitt, E.; Van den Abbeele, A. D.; Henson, J. W.; Li, X.; Gelman, R.; Burstein, H. J.; Kasparian, E.; Kirsch, D. G.; Crawford, A.; Hochberg, F.; Winer, E. P. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2008, 26, 1993-1999.
38. Lin, N. U.; Diéras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H. J.; Roché, H.; Liu, M. C.; Greil, R.; Ciruelos, E.; Loibl, S.; Gori, S.; Wardley, A.; Yardley, D.; Brufsky, A.; Blum, J. L.; Rubin, S. D.; Dharan, B.; Steplewski, K.; Zembryki, D.; Oliva, C.; Roychowdhury, D.; Paoletti, P.; Winer, E. P. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 2009, 15, 1452-1459.
39. Sutherland, S.; Ashley, S.; Miles, D.; Chan, S.; Wardley, A.; Davidson, N.; Bhatti, R.; Shehata, M.; Nouras, H.; Camburn, T.; Johnston, S.R. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br. J. Cancer 2010, 102, 995-1002.
40. Metro, G.; Foglietta, J.; Russillo, M.; Stocchi, L.; Vidiri, A.; Giannarelli, D.; Crinò, L.; Papaldo, P.; Mottolese, M.; Cognetti, F.; Fabi, A.; Gori, S. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 2011, 22, 625-630.
41. Fabi, A.; Vidiri, A.; Ferretti, G.; Felici, A.; Papaldo, P.; Carlini, P.; Mirri, A.; Nuzzo, C.; Cognetti, F. Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow? Cancer Invest. 2006, 24, 466-468.
42. Ekenel, M.; Hormigo, A. M.; Peak, S.; Deangelis, L. M.; Abrey, L. E. Capecitabine therapy of central nervous system metastases from breast cancer. J. Neurooncol. 2007, 85, 223-227.
43. Bachelot, T. D; Romieu, G.; Campone, M.; Dieras, V.; Cropet, C; Roche, H. H.; Jimenez, M.; Le Rhun, E.; Pierga, J.; Goncalves, A.; Leheurteur, M.; Domont, J.; Gutierrez, M.; Cure, H.; Ferrero, J.; Labbe, C. LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine © in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole brain radiotherapy (WBR). J. Clin. Oncol. 2011, 29, 509.
44. Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00614978 [Last accessed 1 March2011]
45. Sambade, M. J.; Kimple, R. J.; Camp, J. T.; Peters, E.; Livasy, C. A.; Sartor, C. I.; Shields, J. M. Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 575-581.
46. Emanuel, S. L.; Hughes, T. V.; Adams, M.; Rugg, C. A.; Fuentes-Pesquera, A.; Connolly, P. J.; Pandey, N.; Moreno-Mazza, S.; Butler, J.; Borowski, V.; Middleton, S. A.; Gruninger, R. H.; Story, J. R.; Napier, C.; Hollister, B.; Greenberger, L. M. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol. Pharmacol. 2008, 73, 338-348.
47. Kennecke, H.; Yerushalmi, R.; Woods, R.; Cheang, M. C.; Voduc, D.; Speers, C. H.; Nielsen, T. O.; Gelmon, K. Metastatic behavior of breast cancer subtypes. J. Clin Oncol. 2010, 28, 3271-3277.
48. Van Meter, M. E.; Kim, E. S. Bevacizumab: current updates in treatment. Curr. Opin. Oncol. 2010, 22, 586-591.
49. Friedman, H. S.; Prados, M. D.; Wen, P. Y.; Mikkelsen, T.; Schiff, D.; Abrey, L. E.; Yung, W. K.; Paleologos, N.; Nicholas, M. K.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27, 4733-4740.
50. Gordon, M. S.; Margolin, K.; Talpaz, M.; Sledge, G. W.; Holmgren, E.; Benjamin, R.; Stalter S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 843-850.
51. Socinski, M. A.; Langer, C. J.; Huang, J. E.; Kolb, M. M.; Comptom, P.; Wang, L.; Akerley, W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 2009, 27, 5255-5261.
52. Morgensztern, D.; Govindan, R. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. Clin. Lung Cancer 2008, 9(2), 57-61.
53. Oh, Y.; Stewart, D. J. Systemic therapy for lung cancer brain metastases a rationale for clinical trials. Oncology (Williston Park) 2008, 22, 168-178.
54. Besse, B.; Lasserre, S. F.; Compton, P.; Huang, J.; Augustus, S.; Rohr, U. P. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 2010, 16, 269-278.
55. Carboplatin and bevacizumab for progressive breast cancer brain metastases. Available at: http://clinicaltrial.gov/ct2/results? term=NCT01004172 [last accesed 1 March 2011].
56. Bevacizumab with etoposide and cisplatin in breast cancer patients with brain and/or leptomeningeal metastases. Available at: http://clinicaltrial.gov/ct2/results?term=NCT01281696 [last accesed 1 March 2011].
57. Annunziata, C. M.; O'Shaugnessy, J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin. Cancer Res. 2010, 18, 4517-4526.
58. Anders, C. K.; Winer, E. P.; Ford, J. M.; Dent, R.; Silver, D. P.; Sledge, G. W.; Carey, L. A. Poly(ADP-Ribose) polymerase inhibition: Targeted therapy for triple-negative breast cancer. Clin. Cancer. Res. 2010, 16, 4702-4710.
59. Haffry, B. G.; Yang, Q.; Reiss, M.; Kearney, T.; Higginn, S. A.; Weidhaas, J.; Harris, L.; Hait, W.; Toppmeyer, D. Locoregional rtelapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 2006, 24, 5652-5657.
60. Dent, R.; Trudeau, M.; Pritchard, K. I.; Hanna, W. M.; Kahn, H. K.; Sawka, C. A; Lickley, L. A.; Rawlinson, E.; Sun, P.; Narod, S. A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13(15 Pt 1), 4429-4434.
61. A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis. Available at: http://clinicaltrials.gov/ct2/results?term=NCT01173497 [last accessed 1 March 2011].
62. A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients. Available at: http://clinicaltrials.gov/ct2/results?term=NCT00649207 last accessed 1 March 2011].
63. Lockman, P. R.; Mittapalli, R. K.; Taskar, K. S.; Rudraraju, V.; Gril, B.; Bohn, K. A.; Adkins, C. E.; Roberts, A.; Thorsheim, H. R.; Gaasch, J. A.; Huang, S.; Palmieri, D.; Steeg, P. S.; Smith, Q. R. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 2010, 16, 5664-5678.
64. Palmieri, D.; Lockman, P. R.; Thomas, F. C.; Hua, E.; Herring, J.; Hargrave, E.; Johnson, M.; Flores, N.; Qian, Y.; Vega-Valle, E.; Taskar, K. S.; Rudraraju, V.; Mittapalli, R. K.; Gaasch, J. A.; Bohn, K. A.; Thorsheim, H. R.; Liewehr, D. J.; Davis, S.; Reilly, J. F.; Walker, R.; Bronder, J. L.; Feigenbaum, L.; Steinberg, S. M.; Camphausen, K.; Meltzer, P. S.; Richon, V. M.; Smith, Q. R.; Steeg, P. S. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin. Cancer Res. 2009, 15, 6148-6157.
65. Gril, B.; Palmieri, D.; Qian, Y.; Smart, D.; Ileva, L.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer Res. 2011, 17, 142-153.